Daniel Brennan

Michael Ryskin

Ryan MacDonald

Andrew Brackmann

Tejas Savant

Daniel Arias

David Westenberg

Mark Massaro

Rachel Vatnsdal

Rachel Vatnsdal Olson

Subhalaxmi Nambi

Dan Arias

Douglas Schenkel

Doug Schenkel

Mark [indiscernible]

Mark Schappel

Subbu Nambi

Yuko Oku

- The global AI in Precision Medicine Market was valued at **$1.80 billion in 2023** and is projected to reach **$18.27 billion by 2032**, growing at a **CAGR of 29.37%** from 2024 to 2032.  **[1717115_356e3ff2f9d044b4932d34c2c3b524a2_0]** **[1717115_356e3ff2f9d044b4932d34c2c3b524a2_4]** 
- **Tempus AI** reported a **fourth-quarter loss of $0.18 per share** on **revenues of $200.7 million** in February 2025, which led to a **17% drop in its stock value**.  **[1717115_356e3ff2f9d044b4932d34c2c3b524a2_2]** 
- The company attributed its increased operating expenses to an **expanded sales force and growth in testing volume**.  **[1717115_356e3ff2f9d044b4932d34c2c3b524a2_2]** 
- In November 2023, **Exscientia** entered into a multi-year strategic collaboration with **Tempus** to advance biomarker-driven therapeutic development.  **[1717115_356e3ff2f9d044b4932d34c2c3b524a2_2]** 
- **North America** led the AI in Precision Medicine market in 2023 with approximately **46% market share**, while **Europe** was the fastest-growing region with an estimated **CAGR of 36.13%**.  **[1717115_356e3ff2f9d044b4932d34c2c3b524a2_1]**

Tempus AI Reports Q4 2025 Results Amidst Rapidly Growing AI in Precision Medicine Market

- **Tempus AI** has been **selected by the Advanced Research Projects Agency for Health (ARPA-H)** to provide **contract research organization (CRO) and testing services** for the agency's **ADAPT program**.  **[1717115_54548193252544e1abe35b0fc23f9ad9_0]** 
- The **ADAPT program** aims to **revolutionize cancer treatment** by developing adaptive strategies that leverage biomarkers to target metastatic non-small cell lung, breast, and colorectal cancers, with the ultimate goal of **improving patient survival**.  **[1717115_54548193252544e1abe35b0fc23f9ad9_0]** 
- Tempus will support the program by providing access to its **AI-enabled diagnostics** (including xE, xR, xF+, xM), its **CRO, Compass**, to manage trial operations, and its **data integration expertise**.  **[1717115_54548193252544e1abe35b0fc23f9ad9_0]**

Tempus AI Selected by ARPA-H for ADAPT Program

Tempus AI (TEM)